Validation experiment designed to validate causal mechanisms targeting AAV in mouse. Primary outcome: Validate AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy
Description
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy
Background and Rationale
Parkinson's disease (PD) is characterized by progressive neurodegeneration of dopaminergic neurons in the substantia nigra, with mutations in LRRK2 (leucine-rich repeat kinase 2) being the most common genetic cause of familial PD. LRRK2 G2019S mutation leads to increased kinase activity and enhanced neuronal toxicity, making it an attractive therapeutic target. Gene therapy approaches using adeno-associated virus (AAV) vectors to deliver LRRK2-targeting short hairpin RNAs (shRNAs) or CRISPR systems represent promising strategies for neuroprotection. However, the optimal AAV serotype for efficient transduction of dopaminergic neurons while minimizing off-target effects remains unclear. This validation study compares the efficacy, safety, and specificity of multiple AAV serotypes (AAV2, AAV5, AAV9, AAV-PHP.eB) for LRRK2 knockdown in a mouse model of PD. The experimental design employs stereotactic injection of different AAV serotypes carrying identical LRRK2-targeting constructs into the substantia nigra of transgenic mice expressing human LRRK2 G2019S mutation....
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy
Background and Rationale
Parkinson's disease (PD) is characterized by progressive neurodegeneration of dopaminergic neurons in the substantia nigra, with mutations in LRRK2 (leucine-rich repeat kinase 2) being the most common genetic cause of familial PD. LRRK2 G2019S mutation leads to increased kinase activity and enhanced neuronal toxicity, making it an attractive therapeutic target. Gene therapy approaches using adeno-associated virus (AAV) vectors to deliver LRRK2-targeting short hairpin RNAs (shRNAs) or CRISPR systems represent promising strategies for neuroprotection. However, the optimal AAV serotype for efficient transduction of dopaminergic neurons while minimizing off-target effects remains unclear. This validation study compares the efficacy, safety, and specificity of multiple AAV serotypes (AAV2, AAV5, AAV9, AAV-PHP.eB) for LRRK2 knockdown in a mouse model of PD. The experimental design employs stereotactic injection of different AAV serotypes carrying identical LRRK2-targeting constructs into the substantia nigra of transgenic mice expressing human LRRK2 G2019S mutation. Key measurements include viral transduction efficiency via immunofluorescence, LRRK2 protein and mRNA expression levels, dopaminergic neuron survival, motor function assessments, and biodistribution analysis. Innovation lies in the systematic head-to-head comparison of clinically relevant AAV serotypes under identical conditions, providing critical data for clinical translation. The significance extends beyond PD research, as findings will inform AAV serotype selection for other neurodegenerative diseases targeting the nigrostriatal pathway. This validation experiment addresses a critical knowledge gap in translating LRRK2-targeted gene therapy from preclinical studies to clinical applications.
This experiment directly tests predictions arising from the following hypotheses:
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation
Experimental Protocol
Phase 1 (Days 1-3): Prepare AAV vectors - AAV2, AAV5, AAV9, and AAV-PHP.eB serotypes carrying identical LRRK2 shRNA constructs under U6 promoter with GFP reporter (1×10^12 vg/ml titer). House 8-week-old LRRK2 G2019S transgenic mice (n=60, equal male/female) under standard conditions. Phase 2 (Day 4): Perform stereotactic surgery under isoflurane anesthesia. Inject 2μl AAV suspension bilaterally into substantia nigra (coordinates: AP -3.1, ML ±1.2, DV -4.6 mm from bregma) using Hamilton syringe at 0.2μl/min rate. Groups: AAV2 (n=12), AAV5 (n=12), AAV9 (n=12), PHP.eB (n=12), PBS control (n=12). Phase 3 (Weeks 2-8): Conduct weekly behavioral assessments including rotarod test, cylinder test, and open field analysis. Phase 4 (Week 4): Sacrifice subset (n=6/group) for biodistribution analysis via qPCR of liver, heart, kidney, spleen tissues. Phase 5 (Week 8): Terminal sacrifice remaining mice. Perfuse with 4% PFA, collect brains for immunohistochemistry (TH, GFP, LRRK2 staining) and qRT-PCR analysis. Extract RNA/protein from microdissected substantia nigra for LRRK2 expression quantification via Western blot and qRT-PCR. Perform stereological counting of TH-positive neurons in substantia nigra using unbiased sampling methods.
Expected Outcomes
AAV-PHP.eB will demonstrate highest transduction efficiency with 85-95% GFP-positive dopaminergic neurons compared to 60-70% for AAV9, 45-55% for AAV5, and 30-40% for AAV2
LRRK2 protein levels will be reduced by 70-85% in AAV-PHP.eB group, 60-75% in AAV9, 50-65% in AAV5, and 40-55% in AAV2 groups compared to PBS controls (p<0.001)
Dopaminergic neuron preservation will show 80-90% TH-positive cell survival in AAV-PHP.eB group versus 70-80% in other serotypes and 45-55% in PBS controls
Motor function improvements will be most pronounced in AAV-PHP.eB group with 2-3 fold increase in rotarod performance and 40-50% improvement in cylinder test asymmetry
Biodistribution analysis will reveal lowest peripheral organ transduction in AAV5 group (<0.1% of brain levels) compared to higher systemic spread in AAV9 and PHP.eB (1-5% of brain levels)
Off-target effects in striatal neurons will be minimal (<5%) for all serotypes with specific substantia nigra targeting confirmed by immunohistochemistry
Success Criteria
• Achieve >70% transduction efficiency in dopaminergic neurons for at least two AAV serotypes with statistical significance (p<0.05) between serotypes
• Demonstrate >60% LRRK2 protein knockdown in the most effective serotype compared to controls with consistent results across molecular assays
• Show significant neuroprotection with >75% dopaminergic neuron survival in best-performing serotype versus <60% in controls (p<0.01)
• Observe meaningful motor function improvement (>30% enhancement in at least two behavioral tests) in top-performing serotypes
• Maintain favorable safety profile with peripheral organ transduction <1% of brain levels for preferred serotype
• Establish clear serotype ranking with statistically significant differences (p<0.05) in primary endpoints between top two performers
TARGET GENE
AAV
MODEL SYSTEM
mouse
ESTIMATED COST
$280,000
TIMELINE
12 months
PATHWAY
N/A
SOURCE
wiki
PRIMARY OUTCOME
Validate AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy
Phase 1 (Days 1-3): Prepare AAV vectors - AAV2, AAV5, AAV9, and AAV-PHP.eB serotypes carrying identical LRRK2 shRNA constructs under U6 promoter with GFP reporter (1×10^12 vg/ml titer). House 8-week-old LRRK2 G2019S transgenic mice (n=60, equal male/female) under standard conditions. Phase 2 (Day 4): Perform stereotactic surgery under isoflurane anesthesia. Inject 2μl AAV suspension bilaterally into substantia nigra (coordinates: AP -3.1, ML ±1.2, DV -4.6 mm from bregma) using Hamilton syringe at 0.2μl/min rate. Groups: AAV2 (n=12), AAV5 (n=12), AAV9 (n=12), PHP.eB (n=12), PBS control (n=12). Phase 3 (Weeks 2-8): Conduct weekly behavioral assessments including rotarod test, cylinder test, and open field analysis.
...
Phase 1 (Days 1-3): Prepare AAV vectors - AAV2, AAV5, AAV9, and AAV-PHP.eB serotypes carrying identical LRRK2 shRNA constructs under U6 promoter with GFP reporter (1×10^12 vg/ml titer). House 8-week-old LRRK2 G2019S transgenic mice (n=60, equal male/female) under standard conditions. Phase 2 (Day 4): Perform stereotactic surgery under isoflurane anesthesia. Inject 2μl AAV suspension bilaterally into substantia nigra (coordinates: AP -3.1, ML ±1.2, DV -4.6 mm from bregma) using Hamilton syringe at 0.2μl/min rate. Groups: AAV2 (n=12), AAV5 (n=12), AAV9 (n=12), PHP.eB (n=12), PBS control (n=12). Phase 3 (Weeks 2-8): Conduct weekly behavioral assessments including rotarod test, cylinder test, and open field analysis. Phase 4 (Week 4): Sacrifice subset (n=6/group) for biodistribution analysis via qPCR of liver, heart, kidney, spleen tissues. Phase 5 (Week 8): Terminal sacrifice remaining mice. Perfuse with 4% PFA, collect brains for immunohistochemistry (TH, GFP, LRRK2 staining) and qRT-PCR analysis. Extract RNA/protein from microdissected substantia nigra for LRRK2 expression quantification via Western blot and qRT-PCR. Perform stereological counting of TH-positive neurons in substantia nigra using unbiased sampling methods.
Expected Outcomes
AAV-PHP.eB will demonstrate highest transduction efficiency with 85-95% GFP-positive dopaminergic neurons compared to 60-70% for AAV9, 45-55% for AAV5, and 30-40% for AAV2
LRRK2 protein levels will be reduced by 70-85% in AAV-PHP.eB group, 60-75% in AAV9, 50-65% in AAV5, and 40-55% in AAV2 groups compared to PBS controls (p<0.001)
Dopaminergic neuron preservation will show 80-90% TH-positive cell survival in AAV-PHP.eB group versus 70-80% in other serotypes and 45-55% in PBS controls
Motor function improvements will be most pronounced in AAV-PHP.eB group with 2-3 fold increase in rotaro
...
AAV-PHP.eB will demonstrate highest transduction efficiency with 85-95% GFP-positive dopaminergic neurons compared to 60-70% for AAV9, 45-55% for AAV5, and 30-40% for AAV2
LRRK2 protein levels will be reduced by 70-85% in AAV-PHP.eB group, 60-75% in AAV9, 50-65% in AAV5, and 40-55% in AAV2 groups compared to PBS controls (p<0.001)
Dopaminergic neuron preservation will show 80-90% TH-positive cell survival in AAV-PHP.eB group versus 70-80% in other serotypes and 45-55% in PBS controls
Motor function improvements will be most pronounced in AAV-PHP.eB group with 2-3 fold increase in rotarod performance and 40-50% improvement in cylinder test asymmetry
Biodistribution analysis will reveal lowest peripheral organ transduction in AAV5 group (<0.1% of brain levels) compared to higher systemic spread in AAV9 and PHP.eB (1-5% of brain levels)
Off-target effects in striatal neurons will be minimal (<5%) for all serotypes with specific substantia nigra targeting confirmed by immunohistochemistry
Success Criteria
• Achieve >70% transduction efficiency in dopaminergic neurons for at least two AAV serotypes with statistical significance (p<0.05) between serotypes
• Demonstrate >60% LRRK2 protein knockdown in the most effective serotype compared to controls with consistent results across molecular assays
• Show significant neuroprotection with >75% dopaminergic neuron survival in best-performing serotype versus <60% in controls (p<0.01)
• Observe meaningful motor function improvement (>30% enhancement in at least two behavioral tests) in top-performing serotypes
• Maintain favorable safety profil
...
• Achieve >70% transduction efficiency in dopaminergic neurons for at least two AAV serotypes with statistical significance (p<0.05) between serotypes
• Demonstrate >60% LRRK2 protein knockdown in the most effective serotype compared to controls with consistent results across molecular assays
• Show significant neuroprotection with >75% dopaminergic neuron survival in best-performing serotype versus <60% in controls (p<0.01)
• Observe meaningful motor function improvement (>30% enhancement in at least two behavioral tests) in top-performing serotypes
• Maintain favorable safety profile with peripheral organ transduction <1% of brain levels for preferred serotype
• Establish clear serotype ranking with statistically significant differences (p<0.05) in primary endpoints between top two performers